Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: Results from clinical trials involving resistance to molecularly targeted therapies have revealed the importance of rational single-agent and combination treatment strategies. In this study, we tested the efficacy of a type 1 insulin-like growth factor receptor (IGF1R)/insulin receptor (IR) tyrosine kinase inhibitor, OSI-906, in combination with a mitogen–activated protein (MAP)–ERK kinase (MEK) 1/2 inhibitor based on evidence that the MAP kinase pathway was upregulated in colorectal cancer cell lines that were resistant to OSI-906. Experimental Design: The antiproliferative effects of OSI-906 and the MEK 1/2 inhibitor U0126 were analyzed both as single agents and in combination in 13 colorectal cancer cell lines in vitro. Apoptosis, downstream effector proteins, and cell cycle were also assessed. In addition, the efficacy of OSI-906 combined with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) was evaluated in vivo using human colorectal cancer xenograft models. Results: The combination of OSI-906 and U0126 resulted in synergistic effects in 11 of 13 colorectal cancer cell lines tested. This synergy was variably associated with apoptosis or cell-cycle arrest in addition to molecular effects on prosurvival pathways. The synergy was also reflected in the in vivo xenograft studies following treatment with the combination of OSI-906 and selumetinib. Conclusions: Results from this study demonstrate synergistic antiproliferative effects in response to the combination of OSI-906 with an MEK 1/2 inhibitor in colorectal cancer cell line models both in vitro and in vivo, which supports the rational combination of OSI-906 with an MEK inhibitor in patients with colorectal cancer. Clin Cancer Res; 19(22); 6219–29. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Self-citationMEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3747 · Cited by 368
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
Cappuzzo, F., Varella-Garcia, M., Finocchiaro, G., Skokan, M., Gajapathy, S., Carnaghi, C., Rimassa, L., Rossi, E., Ligorio, C., Di Tommaso, L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604439 · Cited by 178
Friday, B. B., Yu, C., Dy, G. K., Smith, P. D., Wang, L., Thibodeau, S. N., & Adjei, A. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1430 · Cited by 146
Met acts on Mdm2 via mTOR to signal cell survival during development
Moumen, A., Patané, S., Porras, A., Dono, R., & Maina, F. (2007) · Development · doi:10.1242/dev.02820 · Cited by 95
Cited by
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Epithelial–mesenchymal transition in colorectal cancer metastasis: A system review
Cao, H., Xu, E., Liu, H., Wan, L., & Lai, M. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.05.010 · Cited by 356
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Temraz, S., Mukherji, D., & Shamseddine, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922976 · Cited by 117
The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
Bieghs, L., Johnsen, H. E., Maes, K., Menu, E., Van Valckenborgh, E., Overgaard, M. T., Nyegaard, M., Conover, C. A., Vanderkerken, K., & De Bruyne, E. (2016) · Oncotarget · doi:10.18632/oncotarget.8982 · Cited by 61
“com/oncotarget Akt and MEK-ERK pathways via activating mutations have been reported to be negative markers of drug sensitivity [190, 191].”
Background
Metadata
- Authors
- Flanigan, S. A., Pitts, T. M., Newton, T. P., Kulikowski, G. N., Tan, A. C., McManus, M. C., Spreafico, A., Kachaeva, M. I., Selby, H. M., Tentler, J. J., Eckhardt, S. G., & Leong, S.
- Venue
- Clinical Cancer Research
- Published
- 2013-11-14
- Volume
- 19
- Issue
- 22
- Pages
- 6219-6229
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2071609853
- Cited by
- 57
- References
- 6
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-0145
- The paper
- Flanigan, S. A., Pitts, T. M., Newton, T. P., Kulikowski, G. N., Tan, A. C., McManus, M. C., Spreafico, A., Kachaeva, M. I., Selby, H. M., Tentler, J. J., Eckhardt, S. G., & Leong, S. (2013). Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-0145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.